Search 

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.

Strategikon Pharma is the developer of Clinical Maestro™, which is an end-to-end elegant cloud-based platform to more efficiently budget, source and manage complex clinical programs. We believe that intuitive technology, complete transparency and effective communication between biopharmaceutical companies and providers will revolutionize the productivity of clinical research.

Clinical Maestro™: Modernize the outsourcing

Established in February 1994 with approval from the State Council, Suzhou Industrial Park (SIP) is the first governmental cooperation project between China and Singapore. Covering an administrative area of 278 sqkm, it is home to 1.19 million people, including 807,800 permanent residents. SIP focuses on three main area, Bio-medicine, AI and nanomaterials.
Over 1400 bio-medicine companies are located in SIP including Alphamab Oncology, Innovent and Cstones.
Science & technology development center provide services to entrepreneurial teams who is looking for a place to start up their business.

SynCore Biotechnology Co., Ltd ("SynCore" 4192:TT) is a new drug and medical devices development company that integrates innovative technological platforms with current unmet medical needs. SynCore has a comprehensive pipeline in the therapeutic areas of oncology, ophthalmology, dermatology and infectious diseases, with experienced R&D, regulatory, manufacturing and commercialization teams.

Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.

High-content screening for AI-drug discovery

China Medical City (Taizhou Medical High-tech Zone) is located in Taizhou, an importent city in the Yangtze River Delta. China Medical city covers 30 km2 according its plan,consisting of functional zones of Scientific Research and Development, Manufacting,Exhibition and Trade, Helthcare, Education and Teaching, and Comprehensive Supporting. As the first national level life science hi-tech park, CMC has cooperated with over 70 famous life sicense research and development institutes and over 1300 companies.

The Telocyte Mission:
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer’s disease.

see company website